Page last updated: 2024-11-02

pioglitazone and Precursor Cell Lymphoblastic Leukemia-Lymphoma

pioglitazone has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 1 studies

Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.

Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Nagayama, A1
Ashida, K1
Watanabe, M1
Moritaka, K1
Sonezaki, A1
Kitajima, Y1
Takahashi, H1
Yoshinobu, S1
Iwata, S1
Yasuda, J1
Hasuzawa, N1
Ozono, S1
Motomura, S1
Nomura, M1

Other Studies

1 other study available for pioglitazone and Precursor Cell Lymphoblastic Leukemia-Lymphoma

ArticleYear
Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Benzhydryl Compounds; Bone Marrow Transplantation; Drug Therapy, Combination; Female; Glucosides; Hu

2021